alpelisib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
phosphatidylinositol 3-kinase inhibitors, antineoplastics 5328 1217486-61-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • alpelisib
  • piqray
  • BYL-719
  • NVP-BYL-719
Alpelisib is an inhibitor of phosphatidylinositol-3- kinase (PI3K) with inhibitory activity predominantly against PI3Kalpha. Gain-of-function mutations in the gene encoding the catalytic alpha-subunit of PI3K (PIK3CA) lead to activation of PI3Kalpha and Akt-signaling, cellular transformation and the generation of tumors in in vitro and in vivo models.
  • Molecular weight: 441.47
  • Formula: C19H22F3N5O2S
  • CLOGP: 2.13
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 101.21
  • ALOGS: -4.92
  • ROTB: 5

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
April 24, 2019 FDA NOVARTIS PHARMS CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperglycaemia 1295.77 34.09 337 3389 34734 46647602
Rash 497.19 34.09 321 3405 356191 46326145
Blood glucose increased 264.52 34.09 124 3602 71889 46610447
Malignant neoplasm progression 158.83 34.09 85 3641 64841 46617495
Breast cancer metastatic 138.80 34.09 49 3677 13629 46668707
Hyperglycaemic hyperosmolar nonketotic syndrome 128.26 34.09 24 3702 507 46681829
Diarrhoea 104.06 34.09 170 3556 559432 46122904
Diabetic ketoacidosis 97.59 34.09 41 3685 18169 46664167
Stomatitis 73.31 34.09 53 3673 68244 46614092
Metastases to liver 60.31 34.09 30 3696 19555 46662781
Mucosal inflammation 50.55 34.09 34 3692 38942 46643394
Breast cancer 45.79 34.09 34 3692 45484 46636852
Metastases to bone 42.92 34.09 23 3703 17453 46664883
Death 42.78 34.09 87 3639 335461 46346875
Ketoacidosis 39.43 34.09 14 3712 3941 46678395
Diabetes mellitus 38.68 34.09 32 3694 50033 46632303
Decreased appetite 35.71 34.09 59 3667 193777 46488559

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC L01EM03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Phosphatidylinositol-3-kinase (Pi3K) inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Germline BRCA-mutated, HER2-negative metastatic breast cancer indication 767444009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.6 acidic
pKa2 13.49 acidic
pKa3 5.2 Basic
pKa4 2.4 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
150MG PIQRAY NOVARTIS N212526 May 24, 2019 RX TABLET ORAL May 24, 2024 NEW CHEMICAL ENTITY
200MG PIQRAY NOVARTIS N212526 May 24, 2019 RX TABLET ORAL May 24, 2024 NEW CHEMICAL ENTITY
50MG PIQRAY NOVARTIS N212526 May 24, 2019 RX TABLET ORAL May 24, 2024 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Kinase INHIBITOR IC50 8.34 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
08W5N2C97Q UNII
4038445 VANDF
C4055478 UMLSCUI
1LT PDB_CHEM_ID
CHEMBL2396661 ChEMBL_ID
DB12015 DRUGBANK_ID
D11011 KEGG_DRUG
56649450 PUBCHEM_CID
9833 INN_ID
C585539 MESH_SUPPLEMENTAL_RECORD_UI
7955 IUPHAR_LIGAND_ID
2169285 RXNORM
317932 MMSL
37038 MMSL
d09294 MMSL
018005 NDDF
788050002 SNOMEDCT_US
788079009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PIQRAY HUMAN PRESCRIPTION DRUG LABEL 1 0078-0701 TABLET 200 mg ORAL NDA 31 sections
PIQRAY HUMAN PRESCRIPTION DRUG LABEL 1 0078-0708 TABLET 150 mg ORAL NDA 31 sections